Teva

Latest stories

17h
The Verge
New migraine drugs promise relief — but at a steep pricea lot at stake." The four pharmaceutical companies developing the drugs — Alde
New migraine drugs promise relief — but at a steep price
The Verge / Posted 17 hours ago
a lot at stake." The four pharmaceutical companies developing the drugs — Alder BioPharmaceuticals, Amgen, Eli Lilly, and Teva — are all testing slightly different antibodies, administered at different times. (Allergan is also developing a... Read more
1d
FOX Business
Will Deckers Outdoor Heat Up or Cool Off?top-line figures. Sales of the key Uggs line were up just 1%, and a large drop
Will Deckers Outdoor Heat Up or Cool Off?
FOX Business / Posted yesterday
top-line figures. Sales of the key Uggs line were up just 1%, and a large drop in the Sanuk brand offset revenue gains from Teva and Hoka One One. In response, Deckers cut its guidance on the sales front by about $100 million, and cuts to adjusted... Read more
1d
FOX Business
Will Deckers Outdoor Heat Up or Cool Off?top-line figures. Sales of the key Uggs line were up just 1%, and a large drop
Will Deckers Outdoor Heat Up or Cool Off?
FOX Business / Posted yesterday
top-line figures. Sales of the key Uggs line were up just 1%, and a large drop in the Sanuk brand offset revenue gains from Teva and Hoka One One. In response, Deckers cut its guidance on the sales front by about $100 million, and cuts to adjusted... Read more
1d
Reuters
Allergan CEO says company is 'weeks away' from closing Teva dealBrent Saunders said on Monday the company expects to close the $40.5 billion sa
Allergan CEO says company is 'weeks away' from closing Teva deal
Reuters / Posted yesterday
Brent Saunders said on Monday the company expects to close the $40.5 billion sale of its generic medicines portfolio to Teva Pharmaceutical Industries Ltd (TEVA.TA) in a matter of weeks, opening the door for new acquisitions. While Allergan... Read more
5d
J Weekly
Bay Area teachers earn Diller Awardsin the midweek program. For the past decade, Shapiro has organized wilderness
Bay Area teachers earn Diller Awards
J Weekly / Posted 5 days ago
in the midweek program. For the past decade, Shapiro has organized wilderness and coming-of-age programs for Wild Earth, Teva and Kallah. She contributes to curriculum development for Wilderness Torah’s B’naiture program and runs an independent... Read more
5d
examiner.com
Sales are happening at Target, Kmart, Kohl’s and Academy Sports + Outdoorsbrands from Jantzen, Nike, Wearabouts, BCG, Hurley, Gerry, Speedo, Burnside, Oc
Sales are happening at Target, Kmart, Kohl’s and Academy Sports + Outdoors
examiner.com / Posted 5 days ago
brands from Jantzen, Nike, Wearabouts, BCG, Hurley, Gerry, Speedo, Burnside, Ocean Current and Reef. Add men’s or women’s Teva sandals for $19.99, men’s or women’s Teva Sport sandals for $39.99, women’s Reef sandals for $28.99 and men’s Reef... Read more
6d
The Nashua Telegraph
Council OKs law firm for inquiryto five drug companies. They are: Purdue Pharma, which manufactures OxyContin;
Council OKs law firm for inquiry
The Nashua Telegraph / Posted 6 days ago
to five drug companies. They are: Purdue Pharma, which manufactures OxyContin; Endo Pharmaceutical; Janssen; Actavis; and Teva. The companies refused to provide any documents, claiming the state's use of a law firm on a contingency-fee counsel... Read more
6d
FOX Business
3 Healthcare Stocks Bears Are Wrong Abouthasn't gone unnoticed by its CEO, either: Phillip Frost -- a billionaire health
3 Healthcare Stocks Bears Are Wrong About
FOX Business / Posted 6 days ago
hasn't gone unnoticed by its CEO, either: Phillip Frost -- a billionaire healthcare entrepreneur and former executive at Teva Pharmaceutical -- recently added more than 47 million shares of Opko's stock to his portfolio, bringing his current... Read more
6d
FOX Business
3 Healthcare Stocks Bears Are Wrong Abouthasn't gone unnoticed by its CEO, either: Phillip Frost -- a billionaire health
3 Healthcare Stocks Bears Are Wrong About
FOX Business / Posted 6 days ago
hasn't gone unnoticed by its CEO, either: Phillip Frost -- a billionaire healthcare entrepreneur and former executive at Teva Pharmaceutical -- recently added more than 47 million shares of Opko's stock to his portfolio, bringing his current... Read more
7d
The Economic Times
Pharma exports growth heading for a sharp decline: Crisiland June 2015 - a fraction of the 840 garnered by global pharmaceutical compani
Pharma exports growth heading for a sharp decline: Crisil
The Economic Times / Posted 7 days ago
and June 2015 - a fraction of the 840 garnered by global pharmaceutical companies. Their global generic competitors such as Teva and Mylan had 48 and 33 NDAs to their credit as of February 2016," Crisil Research Director Ajay Srinivasan... Read more
2 related stories
7d
Market Watch
AstraZeneca asthma drug shows positive resultstheir asthma with existing inhaled drugs and tablets. If approved, it will join
AstraZeneca asthma drug shows positive results
Market Watch / Posted 7 days ago
their asthma with existing inhaled drugs and tablets. If approved, it will join a crowded market: GlaxoSmithKline PLC and Teva Pharmaceutical Industries Ltd. have already launched similar treatments. Still, Astra hopes its drug will win favor... Read more
10d
FOX Business
5 Stocks We're Never SellingAs such, I'm looking forward to his plans for the company once Allergan's gener
5 Stocks We're Never Selling
FOX Business / Posted 10 days ago
As such, I'm looking forward to his plans for the company once Allergan's generic drug unit is safely in the hands of Teva Pharmaceutical Industries later this summer. Aside from Saunder's acumen at deal-making, Allergan also sports a diverse... Read more
10d
FOX Business
5 Stocks We're Never SellingAs such, I'm looking forward to his plans for the company once Allergan's gener
5 Stocks We're Never Selling
FOX Business / Posted 10 days ago
As such, I'm looking forward to his plans for the company once Allergan's generic drug unit is safely in the hands of Teva Pharmaceutical Industries later this summer. Aside from Saunder's acumen at deal-making, Allergan also sports a diverse... Read more
11d
Fortune
Big Pharma Innovation in Small PlacesCodiak BioSciences, and Don Nicholson, who left Merck to lead Nimbus Therapeuti
Big Pharma Innovation in Small Places
Fortune / Posted 11 days ago
Codiak BioSciences, and Don Nicholson, who left Merck to lead Nimbus Therapeutics. Jeremy Levin, ex-CEO of generic giant Teva Pharmaceuticals teva, became head of Ovid Therapeutics, targeting rare neurological diseases. Says biotech recruiter... Read more
11d
FOX Business
Down 27%, Is It Time to Buy Allergan Stock? 3 Things You Need to Knoweveryone else is wrong for thinking the stock is worth just $223 and change. H
Down 27%, Is It Time to Buy Allergan Stock? 3 Things You Need to Know
FOX Business / Posted 11 days ago
everyone else is wrong for thinking the stock is worth just $223 and change. Here are three reasons why. Thing No. 1: Teva Allergan today is a company largely defined by its debt load, which at more than $40 billion net of cash on hand, is... Read more
11d
FOX Business
Down 27%, Is It Time to Buy Allergan Stock? 3 Things You Need to Knoweveryone else is wrong for thinking the stock is worth just $223 and change. H
Down 27%, Is It Time to Buy Allergan Stock? 3 Things You Need to Know
FOX Business / Posted 11 days ago
everyone else is wrong for thinking the stock is worth just $223 and change. Here are three reasons why. Thing No. 1: Teva Continue Reading Below Allergan today is a company largely defined by its debt load, which at more than $40 billion... Read more
11d
TheStreet.com
Mylan tacks on another generics company on the cheapthe apple of Mylan's eye. The company offered $29 billion for the generics drug
Mylan tacks on another generics company on the cheap
TheStreet.com / Posted 11 days ago
the apple of Mylan's eye. The company offered $29 billion for the generics drugmaker in April 2015, but was beaten out by Teva Pharmaceuticals (TEVA - Get Report), who paid $40.5 billion in the deal. Renaissance, apparently, was an opportune... Read more
11d
CNBC
Allergan rises as Goldman Sachs says the stock is 'primed for growth'business model focused on branded growth pharma; 2) a reloaded balance sheet po
Allergan rises as Goldman Sachs says the stock is 'primed for growth'
CNBC / Posted 11 days ago
business model focused on branded growth pharma; 2) a reloaded balance sheet poised to de-lever from 4X to 1.5X post-TEVA; 3) $10 billion share repo authorization sending a clear signal of management confidence; 4) a double digit topline... Read more
11d
TheStreet.com
Sell these 5 stocks now before it's too late.Teva Pharmaceutical Industries Leading things off is $51 billion pharma stock
Sell these 5 stocks now before it's too late.
TheStreet.com / Posted 11 days ago
Teva Pharmaceutical Industries Leading things off is $51 billion pharma stock Teva Pharmaceutical Industries (TEVA - Get Report) . This $51 billion drug maker has had a rough run in 2016, shedding nearly a quarter of its market value since the... Read more
13d
FOX Business
Allergan Launches $10B Share Buyback Programbeen determined. Allergan said this is dependent on the receipt of proceeds fro
Allergan Launches $10B Share Buyback Program
FOX Business / Posted 13 days ago
been determined. Allergan said this is dependent on the receipt of proceeds from the sale of its Actavis Generics unit to Teva Pharmaceutical Industries. Last July, Allergan and Teva agreed to the nearly $41 billion sale, although its closing has... Read more
6 related stories
13d
FOX Business
Allergan Launches $10B Share Buyback Programbeen determined. Allergan said this is dependent on the receipt of proceeds fro
Allergan Launches $10B Share Buyback Program
FOX Business / Posted 13 days ago
been determined. Allergan said this is dependent on the receipt of proceeds from the sale of its Actavis Generics unit to Teva Pharmaceutical Industries. Last July, Allergan and Teva agreed to the nearly $41 billion sale, although its closing has... Read more
6 related stories
13d
Arkansas Democrat-Gazette
Business news in briefin morning trading Tuesday. The share buyback plan is contingent on the sale o
Business news in brief
Arkansas Democrat-Gazette / Posted 13 days ago
in morning trading Tuesday. The share buyback plan is contingent on the sale of the drug developer's generics unit to Teva, which is expected to close by the end of the year. Meanwhile, the company is consolidating its executive team under... Read more
14d
The Financial Express
Big stock buyback: Allergen plans $10 b share repurchaselift its shares 4 percent. The Dublin drugmaker on Tuesday said the planned $4
Big stock buyback: Allergen plans $10 b share repurchase
The Financial Express / Posted 14 days ago
lift its shares 4 percent. The Dublin drugmaker on Tuesday said the planned $40 billion sale of its generics business to Teva Pharmaceutical Industries will close next month and that it will use $8 billion of the money to pay down company... Read more
7 related stories
14d
TheStreet.com
Israeli stocks are dragged down by Teva PharmaceuticalThe worldwide selloff in biotech stocks and the lack of performance by generic
Israeli stocks are dragged down by Teva Pharmaceutical
TheStreet.com / Posted 14 days ago
The worldwide selloff in biotech stocks and the lack of performance by generic drug giant Teva Pharmaceutical Industries(TEVA - Get Report) has hampered Israeli stocks thus far in 2016. Dig a little deeper into the indexes, however, and it's clear... Read more
14d
Business Wire
ERYTECH meldet Höhepunkte der Geschäftsentwicklung und Finanzkennzahlen für das 1. Quartal 2016mit Orphan Europe (Recordati-Gruppe) eine Lizenz- und Vertriebspartnerschaft fü
ERYTECH meldet Höhepunkte der Geschäftsentwicklung und Finanzkennzahlen für das 1. Quartal 2016
Business Wire / Posted 14 days ago
mit Orphan Europe (Recordati-Gruppe) eine Lizenz- und Vertriebspartnerschaft für ERY-ASP bei ALL und AML in Europa und mit TEVA für ALL in Israel getroffen, die das Medikament unter dem Markennamen GRASPA® vermarkten werden. ERYTECH ist am... Read more
682 related stories
14d
Kelowna Capital News
DeHart: Make an impression with new flooringintroducing new brands of Kari Lagerfeld, Bzees by Naturalizer, Feiyue, Ipanema
DeHart: Make an impression with new flooring
Kelowna Capital News / Posted 14 days ago
introducing new brands of Kari Lagerfeld, Bzees by Naturalizer, Feiyue, Ipanema, Vince Camuto, Keen, HiTech, Columbia, Teva and Merrell. Tickets $10 are redeemable towards your footwear purchase. Prices are 20% off regular, sale and... Read more
14d
BC Local News
DeHart: Make an impression with new flooringintroducing new brands of Kari Lagerfeld, Bzees by Naturalizer, Feiyue, Ipanema
DeHart: Make an impression with new flooring
BC Local News / Posted 14 days ago
introducing new brands of Kari Lagerfeld, Bzees by Naturalizer, Feiyue, Ipanema, Vince Camuto, Keen, HiTech, Columbia, Teva and Merrell. Tickets $10 are redeemable towards your footwear purchase. Prices are 20% off regular, sale and... Read more
14d
TheStreet.com
Here's why you should buy shares of powerhouse drug maker allerganTeva is awaiting clearance from the Federal Trade Commission to purchase Allerg
Here's why you should buy shares of powerhouse drug maker allergan
TheStreet.com / Posted 14 days ago
Teva is awaiting clearance from the Federal Trade Commission to purchase Allergan's generic drugs division in a deal worth $40.5 billion. The purchase is expected to go through by the end of next month, and it would effectively free Allergan from its... Read more
7 related stories
14d
Connecticut Post
Allergan plans to buy back $10B in shares, posts 1Q profitannounced Tuesday, May 10. The share buyback plan is contingent on the sale of
Allergan plans to buy back $10B in shares, posts 1Q profit
Connecticut Post / Posted 14 days ago
announced Tuesday, May 10. The share buyback plan is contingent on the sale of the drug developer's generics unit to Teva, which is expected to close by the end of the year. Meanwhile, the company is consolidating its executive team under... Read more
81 related stories
14d
Philadelphia Phillies
Phillies to Celebrate Inaugural 'PLAY BALL WEEKEND' as part of League-Wide Support of Youth Participation in Baseball & Softballheld in their honor before that night's 7:05 p.m. Phillies-Reds game. Plus, all
Phillies to Celebrate Inaugural 'PLAY BALL WEEKEND' as part of League-Wide Support of Youth Participation in Baseball & Softball
Philadelphia Phillies / Posted 14 days ago
held in their honor before that night's 7:05 p.m. Phillies-Reds game. Plus, all fans receive a Phillies Cap, courtesy of Teva Respiratory. Cap Exchange As part of 'Play Ball' weekend, nine lucky youngsters will be randomly selected to exchange... Read more
14d
TheStreet.com
Cramer sees more upside in AllerganHowever, Teva quelled those rumors during its first quarter earnings report Mon
Cramer sees more upside in Allergan
TheStreet.com / Posted 14 days ago
However, Teva quelled those rumors during its first quarter earnings report Monday, noting that it expected to close the deal by the end of June. Jim Cramer, founder of TheStreet, sees Allergan as an accretive company. "It very much looks like a... Read more
7 related stories
14d
TheStreet.com
All eyes on teva's pipeline as allergan generic deal nears completion"The opportunities in the U.S. generic market and in the global generic space a
All eyes on teva's pipeline as allergan generic deal nears completion
TheStreet.com / Posted 14 days ago
"The opportunities in the U.S. generic market and in the global generic space are huge," Teva CEO and president Erez Vigodman told investors on a Monday night call following the release of its first quarter earnings. "And we strongly believe that... Read more
14d
Stamford Advocate
Allergan plans to buy back $10B in shares, posts 1Q profitannounced Tuesday, May 10. The share buyback plan is contingent on the sale of
Allergan plans to buy back $10B in shares, posts 1Q profit
Stamford Advocate / Posted 14 days ago
announced Tuesday, May 10. The share buyback plan is contingent on the sale of the drug developer's generics unit to Teva, which is expected to close by the end of the year. Meanwhile, the company is consolidating its executive team under... Read more
81 related stories
14d
Chattanooga Times Free Press
Allergan plans to buy back $10B in shares, posts 1Q profitannounced Tuesday, May 10. The share buyback plan is contingent on the sale of
Allergan plans to buy back $10B in shares, posts 1Q profit
Chattanooga Times Free Press / Posted 14 days ago
announced Tuesday, May 10. The share buyback plan is contingent on the sale of the drug developer's generics unit to Teva, which is expected to close by the end of the year. Meanwhile, the company is consolidating its executive team under... Read more
81 related stories
14d
Your Hometown Lima Stations
Allergan plans to buy back $10B in shares, posts 1Q profit2 percent in premarket trading. The share buyback plan is contingent on the sa
Allergan plans to buy back $10B in shares, posts 1Q profit
Your Hometown Lima Stations / Posted 14 days ago
2 percent in premarket trading. The share buyback plan is contingent on the sale of the drug developer's generics unit to Teva, which is expected to close by the end of the year. The announcement came as the Dublin-based company swung to a... Read more
81 related stories
14d
The Irish Times
Allergan profit beats on strong sales of Botox and Restasisrepurchase program of up to $10 billion. The buyback follows Allergan’s agreem
Allergan profit beats on strong sales of Botox and Restasis
The Irish Times / Posted 14 days ago
repurchase program of up to $10 billion. The buyback follows Allergan’s agreement to sell its generic drug business to Teva Pharmaceutical Industries Ltd for $40.5 billion. That deal is expected to close in June. The company’s shares were up... Read more
6 related stories
14d
TheStreet.com
Allergan authorizes $10 billion buy back, beats estimatesCEO and president of Allergan in a press release. "As we think about our capita
Allergan authorizes $10 billion buy back, beats estimates
TheStreet.com / Posted 14 days ago
CEO and president of Allergan in a press release. "As we think about our capital deployment options post the close of the Teva transaction, in addition to the stock repurchase program, we will have the ability to pay down debt to maintain our... Read more
6 related stories
14d
FOX Business
Allergan Plans Share Buyback Program Of Up To $10Bfavorable market conditions persist." The buyback can only start after the comp
Allergan Plans Share Buyback Program Of Up To $10B
FOX Business / Posted 14 days ago
favorable market conditions persist." The buyback can only start after the company divests its global generics business to Teva, projected to be completed by the end of June 2016. Allergan said it can choose to end the buyback at any... Read more
2 related stories
14d
FOX Business
Allergan Plans Share Buyback Program Of Up To $10Bfavorable market conditions persist." The buyback can only start after the comp
Allergan Plans Share Buyback Program Of Up To $10B
FOX Business / Posted 14 days ago
favorable market conditions persist." The buyback can only start after the company divests its global generics business to Teva, projected to be completed by the end of June 2016. Allergan said it can choose to end the buyback at any... Read more
2 related stories
14d
Channel NewsAsia
Allergan profit beats on strong sales of Botox and Restasisrepurchase program of up to US$10 billion. The buyback follows Allergan's agre
Allergan profit beats on strong sales of Botox and Restasis
Channel NewsAsia / Posted 14 days ago
repurchase program of up to US$10 billion. The buyback follows Allergan's agreement to sell its generic drug business to Teva Pharmaceutical Industries Ltd for US$40.5 billion. That deal is expected to close in June. The company's shares were up... Read more
6 related stories
14d
Salon.com
Allergan plans to buy back $10 billion stockand muscle spasm treatment Botox. The buyback plan is contingent on the sale o
Allergan plans to buy back $10 billion stock
Salon.com / Posted 14 days ago
and muscle spasm treatment Botox. The buyback plan is contingent on the sale of the drug developer’s generics unit to Teva, which is expected to close by the end of the year. The announcement came as the Dublin-based company swung to a... Read more
81 related stories
14d
Island Packet
Allergan plans to buy back $10 billion stockand muscle spasm treatment Botox. The buyback plan is contingent on the sale o
Allergan plans to buy back $10 billion stock
Island Packet / Posted 14 days ago
and muscle spasm treatment Botox. The buyback plan is contingent on the sale of the drug developer's generics unit to Teva, which is expected to close by the end of the year. The announcement came as the Dublin-based company swung to a... Read more
81 related stories
14d
Daily Herald
Allergan plans to buy back $10 billion stockand muscle spasm treatment Botox. The buyback plan is contingent on the sale o
Allergan plans to buy back $10 billion stock
Daily Herald / Posted 14 days ago
and muscle spasm treatment Botox. The buyback plan is contingent on the sale of the drug developer's generics unit to Teva, which is expected to close by the end of the year. The announcement came as the Dublin-based company swung to a... Read more
81 related stories
14d
ABC News
Allergan Plans to Buy Back $10 Billion Stockand muscle spasm treatment Botox. The buyback plan is contingent on the sale o
Allergan Plans to Buy Back $10 Billion Stock
ABC News / Posted 14 days ago
and muscle spasm treatment Botox. The buyback plan is contingent on the sale of the drug developer's generics unit to Teva, which is expected to close by the end of the year. The announcement came as the Dublin-based company swung to a... Read more
81 related stories
14d
FOX Business
Allergan Realigns Executive Team, Outlines $10B Stock Buybacklast month, after the Obama administration issued rules designed to stymie such
Allergan Realigns Executive Team, Outlines $10B Stock Buyback
FOX Business / Posted 14 days ago
last month, after the Obama administration issued rules designed to stymie such tax-lowering inversion deals. Meanwhile, Teva Pharmaceutical Industries is moving ahead with plans to buy Allergan's generic drugs business for $40.5 billion, which... Read more
7 related stories
14d
FOX Business
Allergan Realigns Executive Team, Outlines $10B Stock Buybacklast month, after the Obama administration issued rules designed to stymie such
Allergan Realigns Executive Team, Outlines $10B Stock Buyback
FOX Business / Posted 14 days ago
last month, after the Obama administration issued rules designed to stymie such tax-lowering inversion deals. Meanwhile, Teva Pharmaceutical Industries is moving ahead with plans to buy Allergan's generic drugs business for $40.5 billion, which... Read more
7 related stories
14d
Market Watch
Allergan OKs $10B share buyback, sales fall shortlast month, after the Obama administration issued rules designed to stymie such
Allergan OKs $10B share buyback, sales fall short
Market Watch / Posted 14 days ago
last month, after the Obama administration issued rules designed to stymie such tax-lowering inversion deals. Meanwhile, Teva Pharmaceutical Industries Ltd. is moving ahead with plans to buy Allergan's generic drugs business for $40.5 billion,... Read more
7 related stories
14d
Market Watch
Allergan plans share buyback program of up to $10Band "if favorable market conditions persist." The buyback can only start after
Allergan plans share buyback program of up to $10B
Market Watch / Posted 14 days ago
and "if favorable market conditions persist." The buyback can only start after the company divests its global generics business to Teva, projected to be completed by the end of June 2016. Allergan said it can choose to end the buyback at an... Read more
2 related stories
14d
iol.co.za
Higher health stocks, falling oil leave S&P 500 flat1.13 percent increase, while energy and materials sectors both tumbled 1.25 per
Higher health stocks, falling oil leave S&P 500 flat
iol.co.za / Posted 14 days ago
1.13 percent increase, while energy and materials sectors both tumbled 1.25 percent. Allergan surged 5.98 percent. Teva Pharmaceutical Industries said it still expected its $40.5 billion acquisition of Allergan's generic drug business to... Read more
25 related stories
15d
The Register NorthJersey.com
Third-quarter net rose for Teaneck-based Phibro Animal Healtha year ago. During the period the company announced its launch of the treatmen
Third-quarter net rose for Teaneck-based Phibro Animal Health
The Register NorthJersey.com / Posted 15 days ago
a year ago. During the period the company announced its launch of the treatment Bendeka with Eagle's marketing partner Teva Pharmaceutical Industries. "Our business outlook for the company remains bright,'' Scott Tarriff, president and chief... Read more
More

People in this news